Tokyo, Japan – February 18, 2025 – Neusignal Therapeutics, Inc., a Tokyo-based company focused on commercializing early-stage drug discovery from Tohoku University, today announced that it has provided its proprietary Alzheimer’s treatment candidate, NTX-083, for an investigator-initiated clinical trial in healthy adults, now underway at the University of Tokyo Hospital (UTokyo Hospital).
Background
Neusignal Therapeutics has been developing NTX-083 as a treatment for Alzheimer’s disease, with support from the Japan Agency for Medical Research and Development (AMED) under its Strengthening Program for Pharmaceutical Startup Ecosystem (3rd Round). Neusignal Therapeutics has now supplied the investigational drug for an investigator-initiated clinical trial in healthy adults being conducted at UTokyo Hospital, marking the first-in-human administration of the drug globally.
The trial aims to assess the safety and tolerability of NTX-083. Neusignal Therapeutics is collaborating with UTokyo Hospital, with support from the Tohoku University Faculty of Pharmaceutical Sciences, the AMED Strengthening Program for Pharmaceutical Startup Ecosystem, investors, and other key stakeholders to accelerate the development of this innovative treatment.
This research and development is supported by AMED under project number JP24qfb127005 (subsidized project title: “Development of KATP channel inhibitor NTX-083 for Alzheimer’s disease therapy”).
Company overview
Established: April 2022
Location: 3-11-5 Nihonbashi Honcho, Chuo-ku, Tokyo 103-0023, Japan
Representative Director: Yoshifumi Yoshida
Business activities: Research and development of treatments for dementia and psychiatric disorders, exploration of early-stage drug discovery for brain diseases
Website: https://neusignal-tx.com/
News Headlines